Eli Lilly
and Nvidia
are partnering to build what they call the pharmaceutical industry’s “most powerful” supercomputer and so-called AI factory to help accelerate drug discovery and development across the sector, the companies announced Tuesday.
It’s the latest stride by Nvidia and the pharmaceutical industry to harness AI to help shorten the time it takes to bring cures to patients, while reducing costs at every stage of drug discovery and development. The process typically takes about 10 years on average from dosing the first human with a drug to its launch on the market, said Diogo Rau, Eli Lilly’s chief information and digital officer, in an interview.
“The things that we’re talking about discovering with this kind of power that we have right now, we’re really going to see those benefits in 2030,” Rau said.
